Headlines about Supernus Pharmaceuticals (NASDAQ:SUPN) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Supernus Pharmaceuticals earned a news sentiment score of 0.16 on Accern’s scale. Accern also gave media headlines about the specialty pharmaceutical company an impact score of 45.9781326917379 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news stories that may have impacted Accern’s analysis:
- Use of charts to make investment decisions about Supernus Pharmaceuticals, Inc. (SUPN) – Wall Street Morning (wallstreetmorning.com)
- Supernus Pharma (SUPN) Proposed Private Offering of $350 Million … – StreetInsider.com (streetinsider.com)
- Supernus Pharma (SUPN) Proposed Private Offering of $350 Million of Convertible Senior Notes (streetinsider.com)
- Supernus Announces Proposed Private Offering of $350 Million of Convertible Senior Notes (finance.yahoo.com)
- Supernus Pharmaceuticals (SUPN) Rating Increased to Buy at BidaskClub (americanbankingnews.com)
Shares of Supernus Pharmaceuticals (SUPN) traded down $3.22 during trading hours on Wednesday, hitting $41.68. 779,190 shares of the stock traded hands, compared to its average volume of 674,633. The firm has a market cap of $2,326.90, a PE ratio of 42.36 and a beta of 1.07. Supernus Pharmaceuticals has a one year low of $27.20 and a one year high of $50.04.
Several brokerages recently commented on SUPN. BidaskClub raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 11th. Zacks Investment Research raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a report on Wednesday, January 10th. B. Riley reissued a “buy” rating and issued a $50.00 price objective on shares of Supernus Pharmaceuticals in a report on Monday, November 20th. Janney Montgomery Scott raised shares of Supernus Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $47.00 price objective for the company in a report on Monday, December 4th. Finally, ValuEngine downgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $51.36.
In other news, VP Victor Vaughn sold 55,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $40.11, for a total value of $2,206,050.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Gregory S. Patrick sold 50,000 shares of the business’s stock in a transaction that occurred on Thursday, January 11th. The shares were sold at an average price of $43.56, for a total transaction of $2,178,000.00. The disclosure for this sale can be found here. Insiders sold a total of 165,750 shares of company stock valued at $7,133,973 over the last 90 days. Corporate insiders own 6.70% of the company’s stock.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.